Thermo Fisher posts quarterly results beat as lab products, biopharma services grow

Thermo Fisher Scientific reported first-quarter profit and revenue above Wall Street estimates, driven by growth in laboratory products and biopharma services. That strength offset softness in analytical instruments and specialty diagnostics, indicating a mixed but overall favorable quarter. The beat is likely supportive for the stock, though the article does not mention guidance changes.

Analysis

Thermo Fisher Scientific reported first-quarter profit and revenue above Wall Street estimates, driven by growth in laboratory products and biopharma services. That strength offset softness in analytical instruments and specialty diagnostics, indicating a mixed but overall favorable quarter. The beat is likely supportive for the stock, though the article does not mention guidance changes.